Recap: Veru Q2 Earnings

Shares of Veru VERU rose 7% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 83.33% over the past year to ($0.01), which beat the estimate of ($0.04).

Revenue of $9,943,000 rose by 42.53% year over year, which missed the estimate of $10,970,000.

Looking Ahead

Veru hasn't issued any earnings guidance for the time being.

Veru hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: May 13, 2020

Time: 06:49 PM ET

Webcast URL: https://verupharma.com/investors/presentations-conference-calls/

Price Action

52-week high: $4.74

52-week low: $1.50

Price action over last quarter: down 16.05%

Company Overview

Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Commercial; and Research and Development.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNews
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!